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Aim To investigate whether patients with metabolic syn-
drome (MetS) undergoing total hip or knee replacement 
have an increased risk for pulmonary embolism (PE).
Methods We studied patients undergoing total hip or 
total knee replacement from January 2001 to April 2006. 
The diagnosis of PE was based on a positive finding with 
a chest CT or a lung scan. Components of MetS were de-
fined as 1) BMI≥30 kg/m2, 2) non-fasting preadmission glu-
cose ≥11.1 mmol/L or diagnosis of diabetes, 3) hyperten-
sion, and 4) dyslipidemia. MetS was diagnosed if at least 
three of these components were present.
Results Of 7282 patients, 107 (1.47%) were diagnosed 
with PE. The incidence of PE in patients with 0, 1, 2, 3, and 
4 MetS components was respectively 0.85% (16/1888; 95% 
confidence interval [CI] 0.5%-1.4%), 1.24% (31/2500; 95% 
CI 0.9%-1.8%), 1.76% (34/1936; 95% CI 1.2%-2.5%), 2.64% 
(21/796; 95% CI 1.7%-4.1%), and 3.09% (5/162; 95% CI 
1.1%-7.4%). The independent risk factors for PE were age 
≥70, knee as opposite to hip replacement, bilateral knee 
surgery, congestive heart failure, and MetS or the number 
of MetS components. The odds of PE independently in-
creased 1.6 times (95% CI 1.01-2.56; P = 0.043) for patients 
with MetS and 1.23 times (95% CI 1.02-1.48; P = 0.028) per 
each additional MetS component.
Conclusion Patients with MetS are at increased risk for PE 
after total joint arthroplasty. The increasing number of MetS 
components significantly increased the incidence of PE.
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Metabolic syndrome (MetS) is an increasing health prob-
lem, affecting 30% to 40% of the adult population in the 
USA (1). Its prevalence increases substantially with age. In 
patients older than 50 years, the prevalence is 44% (2) and 
increases in patients older than 60 years to 50% to 60% (3). 
With the increasing prevalence of MetS and an aging US 
population, it is likely that more patients with MetS will be 
undergoing major orthopedic surgeries such as total hip 
and knee arthroplasty.
Patients undergoing total hip and knee replacement sur-
geries are at risk of developing deep venous thrombosis 
(DVT) and pulmonary embolus (PE). Although thrombo-
prophylaxis is routinely used after the surgery, the inci-
dence of PE after hip and knee arthroplasty still remains 
high, between 0.5% and 10% (4-7). Manifestation of PE var-
ies from asymptomatic to fatal. It may be expected that 
one out of 1000 patients undergoing hip and knee arthro-
plasty would die of PE (6,7).
MetS is defined as a cluster of risk factors for atheroscle-
rosis. Several organizations proposed various criteria, but 
all include abnormal glucose metabolism, excessive body 
weight, elevated blood pressure, and abnormal lipid me-
tabolism (8). The diagnosis of MetS is defined by the pres-
ence of 3 or more of these components. Although the 
syndrome is a constellation of factors that promote the 
development of atherosclerotic cardiovascular disease, 
recently it has been associated with venous thrombo-
sis (9,10). A case-control study of patients who were re-
ferred to the thrombosis clinic in tertiary hospitals found 
that MetS was almost twice as common in patients di-
agnosed with idiopathic DVT than in those who did not 
have DVT (9). In patients with acute coronary syndrome 
or acute heart failure, the presence of MetS independent-
ly increased the risk of developing DVT by 2.38 (10). Our 
recent study showed that perioperative hyperglycemia 
>11.1 mg/dL and high body weight (BMI≥30 kg/m2) in-
dependently increased the risk of PE after hip and knee 
arthroplasty (11), but it is currently unknown whether pa-
tients with MetS have an increased risk for thromboembo-
lic events after major orthopedic surgery. The aim of our 
study was to determine whether MetS and MetS compo-
nents were predictors of symptomatic PE in patients un-
dergoing total hip or knee replacement surgery.
MatERIals and MEtHods
This study was approved by Thomas Jefferson Univer-
sity Hospital Institutional Review Board. Electronic 
medical records of patients having undergone total hip or 
total knee replacement from January 1, 2001 to April 30, 
2006 were retrospectively reviewed. We used the same 
data set as in our recently published study (11). In short, 
the study included patients who had undergone elective 
hip or knee arthroplasty, including revisions and bilater-
al procedures. In patients with multiple procedures dur-
ing the study period, only the data from the most recent 
surgical procedure were included to avoid potential bias 
using the same patients with the same risk factors multi-
ple times. The database was searched by ICD-9 codes for 
hip and knee arthroplasty (84.51, 81.53, 81.54, and 81.55) 
from January 1, 2001 to April 30, 2006. These records were 
matched with the Rothman Institute of Orthopedics da-
tabase, which includes all postoperative complications 
experienced by each patient. Only laboratory data within 
1 month prior the surgery were used for the analysis. Pa-
tients were excluded from analysis if they had (a) a diagno-
sis of paresis, paralysis, or cerebral palsy (55 patients); (b) a 
history of coagulopathy (22 patients); or (c) the preopera-
tive placement of a Greenfield filter (23 patients).
The thromboembolic prophylaxis was with warfarin. War-
farin was started on the night of surgery, and the dose of 
the drug varied based on the perceived pharmacodynam-
ics of the patients. In other words, elderly patients received 
lower starting doses (around 5 mg) than healthier and 
larger patients (10 mg). The additional dose was given de-
pending on the response of the patient and it was titrated 
to achieve an International Normalized Ratio between 1.5 
and 2.0. Patients also received 1000 IU of intravenous hep-
arin at the time of hip dislocation during hip arthroplasty 
or prior to inflation of the tourniquet during knee arthro-
plasty. The heparin dosing was not weight-based as it has 
been shown that the lowest effective heparin dose at 1000 
units accomplishes its antithrombotic effect without sub-
jecting patients to potential risk of added bleeding (12). In 
the postoperative period, patients were subjected to ear-
ly mobilization. All patients undergoing joint arthroplasty 
were ambulated early. Patients were required to get out 
of bed and try to walk within a few hours of surgery. They 
were seen at least twice by physical therapists who tried to 
walk the patients and encourage them to self-ambulate. 
Continuous passive-motion (CPM) devices were utilized 
following knee arthroplasties. They were used based on 
patients’ tolerance and preference, so the majority of the 
patients received between 4 to 5 hours of CPM.
Diagnosis of PE was made by computer tomography (CT) 
or lung VQ scan. During the study period, the imaging mo-
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dality of choice for investigation of PE changed to more 
sensitive studies. Prior to May 2001, the modality for inves-
tigation of PE was lung VQ scan. It was replaced by a chest 
spiral CT study until November 2003, when it was upgrad-
ed to a multi-detector CT study. The imaging modality 
changes resulted in an increased detection of PE after hip 
and knee arthroplasty, as we previously reported (13). After 
May 2001, lung VQ scans were utilized only in patients with 
renal failure or allergy to intravenous contrast.
Characteristics of the study patients with and without PE 
and the test results of association between each poten-
tial risk factor and PE are presented in our previous study 
(11). In short, patients with PE were significantly older, had 
higher BMI, higher American Society of Anesthesiologists 
physical status, more frequently had primary unilateral or 
bilateral knee surgery, had longer duration of surgery, and 
more frequently had history of congestive heart failure and 
endocrinological disease than patients without PE (11).
A modified definition of MetS was adapted from The World 
Health Organization (WHO) and the National Cholesterol 
Education Program – Adult Treatment Program III (NCEP/
ATP III) and applied to the data available in our databases 
(8). MetS components were defined as: 1) obesity – body 
mass index (BMI)≥30 kg/m2 (WHO definition), rather than 
waist circumference (NCEP/ATP III), since these data were 
not available; 2) dysglycemia – the glucose component in-
cluded both glucose intolerance and non-fasting preadmis-
sion blood glucose ≥200 mmol/L (modified WHO), because 
patients were not instructed to fast before the preoperative 
visit, and/or diagnosis of diabetes mellitus (WHO and NCEP/
ATP III); 3) elevated blood pressure – preoperative diagno-
sis of hypertension (WHO) was used because preoperative 
blood pressure measurements were not available; and 4) 
dyslipidemia – because of interchangeable use of a preop-
erative diagnosis of hyperlipidemia, hypercholesterolemia, 
and increased lipids for patients with elevated triglycerides, 
cholesterol and decreased HDL in our database, all patients 
with these diagnoses were included (modified WHO and 
NCEP/ATP III) (8). MetS was defined as the presence of three 
or more of the components described above.
statistics
Univariate association between the rate of PE incidence and 
MetS related covariates (MetS indicator, each MetS compo-
nent, and the number of MetS components) was evaluat-
ed using Fisher exact and Mantel-Haenszel tests. Multivari-
ate analysis of the PE incidence rate was performed using 
logistic regression with all independent covariates catego-
rized. The initial model included all potential risk factors for 
PE considered in the previous study (11), not including the 
MetS components. Backward elimination was used to con-
struct a parsimonious core model. To control for the change 
in increased sensitivity to detect PE over time, the year of 
surgery was always included as a covariate. Finally, the co-
variates related to MetS were added to this core model to 
evaluate the effect of MetS on PE while adjusting for other 
risk factors. This resulted in three final multivariate models, 
which included all covariates from the core model plus one 
of the following: (I) the MetS indicator (dichotomous); (II) the 
number of MetS components (0-4) as an ordinal covariate; 
(III) the four individual MetS components as separate pre-
dictors. This modeling approach of having a core model of 
the background variables associated with PE and then add-
ing to it possible factors related to MetS allows comparing 
the predictive values of MetS-related covariates through the 
increase in the log-likelihood of models I-III as compared to 
the core model. Statistical analyses were performed using 
SAS 9.1.3 (SAS Institute Inc., Cary, NC; USA).
REsults
A total of 11 283 patients were reviewed. After exclusion 
of patients with missing data and the data from repeated 
admissions, 7282 patients who underwent elective, prima-
ry or revision, total hip, and knee replacements were ana-
lyzed. Patients were operated on average 15 ± 8 days after 
the preoperative clinic visit.
The overall incidence of PE was 1.47% (107/7282 patients; 
95% confidence interval [CI] 1.2%-1.8%). MetS was present in 
13.2% (958/7282; 95% CI 12.4%-14.0%) of patients. In univari-
ate analysis, patients with MetS had a significantly higher in-
cidence of PE (2.7%, 26/958; 95% CI 1.8%-4.0%) than patients 
without MetS (1.3%, 81/6324; 95% CI 1.0%-1.6%) (P = 0.001) 
(Table 1). Among the four components defining MetS, only 
BMI≥30 kg/m2 and hypertension were univariately associat-
ed with a significant increase in the incidence of PE (Table 1). 
As the number of MetS components increased, so did the 
incidence of postoperative PE (P < 0.001, Figure 1). The inci-
dence of PE in patients with 0, 1, 2, 3, and 4 MetS compo-
nents was respectively 0.85% (16/1888; 95% CI 0.5% - 1.4%), 
1.24% (31/2500; 95% CI 0.9%-1.8%), 1.76% (34/1936; 95% CI 
1.2%-2.5%), 2.64% (21/796; 95% CI 1.7%-4.1%), and 3.09% 
(5/162; 95% CI 1.1%-7.4%) (Figure 1).
In the multivariate core model not including MetS-relat-
ed covariates, the increased risk of PE was significantly 
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associated with age, knee as opposite to hip replacement, 
bilateral knee as opposite to unilateral knee replacement, 
and CHF (Table 2A). Year of surgery was included in the core 
model as described in Methods. During the study period, 
the incidence of diagnosed PE increased (13).
After adjusting for all other significant risk factors, pa-
tients with MetS still had 1.6 (95% CI 1.01-2.56; P = 0.043) 
times greater odds for developing PE than patients with-
out MetS (Table 2B, model I). Considering the number of 
MetS components in the multivariate model controlling 
for other significant risk factors, each additional MetS com-
ponent increased the odds for PE by 1.23 (95% CI 1.02-1.48; 
P = 0.028) (Table 2B, model II). Thus, patients with two MetS 
components had 1.51 (1.232) times (95% CI 1.04-2.19) high-
er odds of PE than patients with no MetS components. The 
increase in the model log-likelihood (from the likelihood of 
the core model) was higher (2.37) when the ordinal num-
ber of MetS components was added to the core model 
than when the dichotomous MetS covariate was added 
(1.90) (Table 2B). This suggests that the number of MetS 
components may have better utility predicting PE than 
MetS as a dichotomous indicator.
When the four covariates defining MetS were added to the 
core multivariate model (model III), only BMI≥30 kg/m2 sig-
nificantly increased the odds of PE, by 2.2 times (95% CI 
1.4-3.4). This suggests that BMI might be the most impor-
tant MetS component regarding the incidence of PE in this 
clinical setting.
dIsCussIon
This study showed that patients with MetS had increased 
risk of inhospital symptomatic PE after total hip and knee 
arthroplasty. The increasing number of MetS components 
taBlE 1. Results of univariate analyses of metabolic syndrome and its components and the incidence of pulmonary embolism (PE) 
after major orthopedic surgery
number (%) of patients
with PE 
(n = 107)
without PE 
(n = 7175)
total 
(n = 7282)
 
P*
Metabolic syndrome yes 26 (2.7)  932 (97.3)  958  0.001
no 81 (1.3) 6243 (98.7) 6324
number of metabolic syndrome components 0 16 (0.85) 1872 (99.15) 1888 <0.003
1 31 (1.24) 2469 (98.76) 2500
2 34 (1.76) 1902 (98.24) 1936
3 21 (2.64)  775 (97.36)  796
4  5 (3.09)  157 (96.91)  162
Individual components of metabolic syndrome
body mass index <30 kg/m2 38 (0.9) 3966 (99.1) 4004 <0.001
≥30 kg/m2 69 (2.1) 3209 (97.9) 3278
dyslipidemia 26 (2.7)  932 (97.3)  958  0.169
hypertension 68 (1.8) 3806 (98.2) 3874  0.032
dysglycemia 19 (2.1)  867 (97.9)  886  0.099
*Mantel-Haenszel (number of components) or Fisher exact test.
FIguRE 1. Incidence of pulmonary embolism (PE) by increas-
ing number of metabolic syndrome (Mets) components. 
*the incidence of PE significantly increased with the number 
of Mets components, P < 0.001 (univariate Mantel-Haenszel 
test). Presented are PE incidence rates and 95% confidence 
intervals (CI). Each additional risk factor increased the odds for 
PE by 1.23 (95% CI 1.02-1.48), P = 0.028 (multivariate logistic 
regression).
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significantly increased the incidence of PE. Overall, the risk 
of PE was increased by 23% for each additional component 
of MetS. The most important MetS component was BMI.
Our findings are consistent with three recent case-control 
studies evaluating MetS and the risk of venous throm-
boembolism (9,10,14). All three studies showed that ele-
vated triglycerides significantly increased the risk for DVT 
(9,10,14), while our study showed that hyperlipidemia was 
not an independent risk factor for PE. This discrepancy 
could possibly be explained using our wider definition 
of dyslipidemia compared to the NCEP/ATP III criteria. In-
deed, mean HDL and ongoing therapy with statins in Ag-
eno’s study (9) and hypercholesterolemia and decreased 
HDL in Ambrosetti’s study (10) were not found to be as-
sociated with an increased risk for DVT. We are not aware 
of a study investigating the correlation between dyslipi-
demia and incidence of thromboembolic events after hip 
and knee arthroplasty in the current literature, although 
there is a growing body of evidence that dyslipidemia in-
creases the risk of venous thromboembolism in the gen-
eral population (15).
Also, our study is consistent with previous studies show-
ing that obesity is a risk factor for PE after hip and knee ar-
throplasty (16,17). Ageno et al (9) and Ambrosetti et al (10) 
found that for the prediction of DVT MetS was indepen-
dent of BMI, but the waist circumference was used as an 
obesity component of MetS. In the study by Ay et al (14), as 
well in this study, MetS was not independent of BMI.
All three MetS case-control studies found that increased 
fasting glucose was not a significant risk factor for DVT 
(9,10,14). Our patients were not instructed to fast before 
blood was sampled for preoperative testing, which pre-
cluded us from using fasting glucose level as a compo-
nent of MS (WHO and NCEP/ATP III definition of MS) (8). 
In our previous study, hyperglycemic patients (blood 
glucose≥11.1 mmol/L) had high incidence of PE (5.1%) 
(11). It is unknown if more aggressive perioperative glyce-
mic control influences the incidence for developing of PE 
after the surgery.
The MetS case-control studies did not find that high blood 
pressure increased the risk of DVT (9,10,14). In our study, 
taBlE 2. Results of multivariate analyses of the incidence of pulmonary embolism after major orthopedic surgery. Part a – results 
from the core model not including the metabolic syndrome related covariates. Part B – results from three models combining the 
covariates from the core model and covariates related to metabolic syndrome: *dichotomous indicator of metabolic syndrome; †the 
number of metabolic syndrome components treated as ordinal covariate; ‡individual metabolic syndrome components considered 
simultaneously
Covariate/base comparison odds ratio (95% confidence interval) P Increase in log-likelihood
a
age (yrs) Overall  0.007§
50-60 /<50 1.43 (0.52- 3.90)  0.486
60-70 /<50 1.80 (0.69 - 4.72)  0.232
70-80 /<50 2.96 (1.15- 7.63)  0.025§
>80 /<50 3.74 (1.33- 10.48)  0.012§
Knee/hip 2.77 (1.73- 4.45) <0.001§
Bilateral knee/unilateral knee 2.19 (1.34- 3.57)  0.002§
Congestive heart failure 3.12 (1.46- 6.68)  0.003§
Year of surgery Overall  0.051§
2002/2001 2.02 (0.74 - 5.51)  0.170
2003/2001 2.06 (0.82 - 5.17)  0.124
2004/2001 3.41 (1.42 - 8.17)  0.006§
2005-6/2001 2.64 (1.10 - 6.32)  0.030§
B
Metabolic syndrome* 1.61 (1.01 - 2.56)  0.043§ 1.90
number of metabolic syndrome components (0-4)† 1.23 (1.02 - 1.48)  0.028§ 2.37
Hypertension‡ 0.93 (0.61 - 1.42)  0.736
dyslipidemia‡ 1.09 (0.68 - 1.72)  0.728
Body mass index ≥30 kg/m2‡ 2.19 (1.42 - 3.36) <0.001§
dysglycemia‡ 0.97 (0.57 - 1.65)  0.916
§statistically significant <0.05.
CLINICAL SCIENCE 360 Croat Med J. 2013;54:355-61
www.cmj.hr
the univariate analysis showed that hypertension increased 
the incidence of PE significantly, but the effect went away 
in the multivariate analysis. In support of this finding, hy-
pertension also was not found to be a risk factor for PE after 
orthopedic surgery (16).
The possible mechanisms for thromboembolism in pa-
tients with MetS are not completely understood. This top-
ic has been reviewed in detail elsewhere (18,19). In short, 
there is no agreement in regards to the initial metabolic 
abnormality. It is either obesity or insulin resistance/glu-
cose intolerance. But there is concurrence that MetS is a 
proinflammatory and prothrombotic state. Obesity in-
creases adipokines and hyperglycemia induces oxidative 
stress, while both can lead to activation of the inflamma-
tory and coagulation cascade.
The limitations of this study are its retrospective data col-
lection and missing baseline preoperative data. However, 
information regarding the outcome (PE) was complete 
and the missing data was spread evenly across the study 
period. We evaluated missing patients with PE and found 
no significant association between the incidence of PE and 
the missing data status (complete vs missing). Therefore, 
the results of the study may have not been skewed despite 
missing a large number of data. Over the study period, the 
mode of the detection of PE was changed. We have previ-
ously published a study that demonstrated increasing sen-
sitivity of imaging modality resulting in a higher probabil-
ity of a positive finding for PE (13). We incorporated year of 
the surgery in our analysis models to adjust for the change 
in the detection modality and the change over time in the 
other possible unforeseen variables. The change in the PE 
detection did not appear to influence out results since 
MetS and the number of MetS components remained in-
dependently significant predictors for PE. Another limita-
tion is the modified definition of MetS. Our definition did 
not include patients who had borderline hypertension, in-
sulin tolerance, impaired fasting glucose, elevated triglyc-
erides, low HDL, and did not consider waist circumference, 
whereas these patients are included in the WHO and ATP 
III definitions of MetS. Indeed, the prevalence of MetS ac-
cording to this modified definition was 13.2%, which was 
less than expected according to US population data (30%-
40%) (1). Our modified definition probably included pa-
tients with more severe pathological conditions and dis-
eases compared to WHO and ATP III definitions (8).
The American Academy of Orthopedic Surgeons rec-
ommended that chemical prophylaxis should be 
based on the risk stratification for PE and the risk of bleed-
ing (http://www.aaos.org/Research/guidelines/PE_guide-
line.pdf ). Data from our study suggest that patients receiv-
ing warfarin for thromboprophylaxis have a greater than 
standard risk for developing PE after hip and knee surgery, 
if they have MetS. Clinicians may use components of MetS 
to stratify the risk for PE after arthroplasty along with older 
age and history of CHF. The diagnosis of MetS or the pres-
ence of its components would alert an anesthesiologist 
of potentially aggressive thromboprophylaxis by the sur-
geon. This may influence the anesthesia and pain manage-
ment choice, eg, if the patient is at greater risk for PE and 
more aggressive antithrombotic therapy is being consid-
ered, then perhaps the decision to place an epidural cath-
eter should be carefully considered.
In summary, this study showed that patients with MetS 
had an increased risk of PE after hip and knee arthroplasty. 
Moreover, the incidence of PE correlated with the number 
of MetS components. The increasing number of MetS com-
ponents significantly increased the incidence of PE. A pro-
spective study is needed to determine if better preopera-
tive control of MetS components decreases the incidence 
of PE after hip and knee total replacement surgery.
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